Article
Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.
Science translational medicine - 15 Jun 2022
Gigoux Mathieu, Holmström Morten O, Zappasodi Roberta, Park Joseph J, Pourpe Stephane, Bozkus Cansu Cimen, Mangarin Levi M B, Redmond David, Verma Svena, Schad Sara, George Mariam M, Venkatesh Divya, Ghosh Arnab, Hoyos David, Molvi Zaki, Kamaz Baransel, Marneth Anna E, Duke William, Leventhal Matthew J, Jan Max, Ho Vincent T, Hobbs Gabriela S, Knudsen Trine Alma, Skov Vibe, Kjær Lasse, Larsen Thomas Stauffer, Hansen Dennis Lund, Lindsley R Coleman, Hasselbalch Hans, Grauslund Jacob H, Lisle Thomas L, Met Özcan, Wilkinson Patrick, Greenbaum Benjamin, Sepulveda Manuel A, Chan Timothy, Rampal Raajit, Andersen Mads H, Abdel-Wahab Omar, Bhardwaj Nina, Wolchok Jedd D, Mullally Ann, Merghoub Taha
Abstract excerpt
The majority of JAK2V617F-negative myeloproliferative neoplasms (MPNs) have disease-initiating frameshift mutations in calreticulin (CALR), resulting in a common carboxyl-terminal mutant fragment (CALRMUT), representing an attractive source of neoantigens for cancer vaccines. However, studies have shown that CALRMUT-specific T cells are rare in patients with CALRMUT MPN for unknown reasons. We examined class I...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.